BATTLE TESTED
IN EOS DISEASE

NUCALA reduced nasal polyp symptoms* and protected against surgery in patients with CRSwNP

NUCALA reduced nasal polyp
symptoms* and protected against
surgery in patients with CRSwNP

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Choose NUCALA for CRSwNP

Red nose icon

Reduced
nasal polyp size†

Red nasal obstruction icon

Reduced
nasal obstruction†

Red cross icon

Reduced repeat surgery‡

View efficacy results

Symptoms include nasal obstruction, nasal discharge, mucus in the throat, loss of smell.

Red quality of life icon

Also choose NUCALA for improvement in quality of life,§ based on SNOT-22

In the SYNAPSE study, all primary and secondary endpoints were met with statistical significance.1

 

†Co-primary endpoints:

Significant improvement in nasal polyp size. LS mean|| change from baseline in total endoscopic nasal polyp score at Week 52: NUCALA + SOC (n=206), –0.87 (baseline score: 5.4) vs placebo + SOC (n=201), 0.06 (baseline score: 5.6); P<0.001.1,2

Significant improvement in nasal obstruction. LS mean|| change from baseline in nasal obstruction VAS score at Weeks 49-52: NUCALA + SOC (n=206), –4.40 (baseline score: 8.9) vs placebo + SOC (n=201), –2.54 (baseline score: 9.0); P<0.001.1,2

See more data

Key secondary endpoint: Time to next nasal polyp surgery up to Week 52: 57% reduction in the proportion of patients who had surgery with NUCALA + SOC vs placebo + SOC, HR: 0.43; P=0.0032.1

View surgery results

Secondary endpoint: Median change from baseline in SNOT-22 total score at Week 52; NUCALA + SOC, 30-point improvement vs placebo + SOC, 14-point improvement; P=0.0032.1

Review the data

View full study design

LS means from analysis using mixed model repeated measures.

Defined as daily mometasone furoate nasal spray in addition to saline nasal irrigations and courses of systemic corticosteroids and/or antibiotics as required.

HR=hazard ratio; IL=interleukin; LS=least squares; SNOT-22=sino-nasal outcome test (22-item); SOC=standard of care; VAS=visual analogue scale.

Red eosinophils icon

NUCALA is the only anti-IL-5 approved for CRSwNP

See other indications for eosinophil-driven diseases

Red checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your nasal polyp patients and practice.

See patient access & support

Autoinjector icon

Administering NUCALA

NUCALA gives appropriate patients the option to self-administer at home.

See CRSwNP dosing & administration

Next: CRSwNP patient types

Eosinophils and Mechanism of Action icon

Eosinophils & MOA 
in CRSwNP

Comorbid asthma & AERD

Comorbidity data

Rep icon

Request a Rep